Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Current Assets (2020 - 2025)

Historic Current Assets for Gain Therapeutics (GANX) over the last 6 years, with Q3 2025 value amounting to $10.5 million.

  • Gain Therapeutics' Current Assets fell 2346.26% to $10.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.5 million, marking a year-over-year decrease of 2346.26%. This contributed to the annual value of $11.6 million for FY2024, which is 3474.01% down from last year.
  • According to the latest figures from Q3 2025, Gain Therapeutics' Current Assets is $10.5 million, which was down 2346.26% from $9.3 million recorded in Q2 2025.
  • Over the past 5 years, Gain Therapeutics' Current Assets peaked at $47.4 million during Q1 2021, and registered a low of $9.3 million during Q2 2025.
  • For the 5-year period, Gain Therapeutics' Current Assets averaged around $22.9 million, with its median value being $18.5 million (2024).
  • Its Current Assets has fluctuated over the past 5 years, first surged by 31970.14% in 2021, then plummeted by 4979.9% in 2025.
  • Quarter analysis of 5 years shows Gain Therapeutics' Current Assets stood at $37.7 million in 2021, then crashed by 44.09% to $21.1 million in 2022, then dropped by 15.71% to $17.8 million in 2023, then plummeted by 34.74% to $11.6 million in 2024, then dropped by 9.35% to $10.5 million in 2025.
  • Its last three reported values are $10.5 million in Q3 2025, $9.3 million for Q2 2025, and $11.2 million during Q1 2025.